PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Princeton, New Jersey and currently employs 24 full-time employees. The company went IPO on 2015-10-01. The firm is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Dr. Frank Bedu-Addo est le President de PDS Biotechnology Corp, il a rejoint l'entreprise depuis 2019.
Quelle est la performance du prix de l'action PDSB ?
Le prix actuel de PDSB est de $0.6847, il a augmenté de 8.21% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de PDS Biotechnology Corp ?
PDS Biotechnology Corp appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de PDS Biotechnology Corp ?
La capitalisation boursière actuelle de PDS Biotechnology Corp est de $35.8M
Est-ce que PDS Biotechnology Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour PDS Biotechnology Corp, y compris 2 achat fort, 6 achat, 1 maintien, 0 vente et 2 vente forte